HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial

This article was originally published in The Tan Sheet

Executive Summary

The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
Advertisement

Related Content

ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
ADAPT Naproxen Signal “Not Sufficiently Compelling” To Halt Trial – Speaker
Aleve Ad
Cardiovascular Risk, Label Reading Not Mentioned In Aleve Ad
Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol
FDA Public Health Advisory Recommends Limited Use Of All NSAIDs
Celebrex Heart Risk Findings In Cancer Study Deals Blow To COX-2s
Celebrex Heart Risk Findings In Cancer Study Deals Blow To COX-2s
NIH Alzheimer’s Trial Based On Industry Support, Not Science – Public Citizen

Topics

Advertisement
UsernamePublicRestriction

Register

PS097688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel